ALK-positive ALCL with TP53 deletion that resisted high-intensity treatment including allo-SCT

Seiichiro Katagiri

Presentation information

Oral Session

Oral Session 1-10D PTCL: Pathophysiology/Prognosis

Fri. Oct 11, 2019 4:30 PM - 5:30 PM No.10 (Tokyo International Forum, 4F G409)

Chair: Takero Shindo (Kyoto University Graduate School of Medicine Hematology Oncology)

[OS1-10D-6] ALK-positive ALCL with TP53 deletion that resisted high-intensity treatment including allo-SCT

Seiichiro Katagiri¹, Daigo Akahane¹, Tamiko Suguro¹, Michiyo Asano¹, Yuko Tanaka¹, Nahoko Furuya¹, Hiroaki Fujimoto¹, Naoya Nakamura², Kazuma Ohyashiki¹ (1.Department of Hematology, Tokyo Medical University, 2.Department of Pathology, Tokai University School of Medicine)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.